Clinical and Experimental Pediatrics

The Korean Pediatric Society (대한소아청소년과학회)
권호 표지

Human Papillomavirus Vaccine

인유두종 바이러스 백신

  • Kim, Kyung Hyo (The Committee on Infectious Diseases, The Korean Pediatric Society) ;
  • Kim, Jong-Hyun (The Committee on Infectious Diseases, The Korean Pediatric Society) ;
  • Park, Su Eun (The Committee on Infectious Diseases, The Korean Pediatric Society) ;
  • Shin, Seon Hee (The Committee on Infectious Diseases, The Korean Pediatric Society) ;
  • Oh, Sung-Hee (The Committee on Infectious Diseases, The Korean Pediatric Society) ;
  • Lee, Hoan Jong (The Committee on Infectious Diseases, The Korean Pediatric Society) ;
  • Jo, Dae Sun (The Committee on Infectious Diseases, The Korean Pediatric Society) ;
  • Choi, Eun Hwa (The Committee on Infectious Diseases, The Korean Pediatric Society) ;
  • Hur, Jae Kyun (The Committee on Infectious Diseases, The Korean Pediatric Society) ;
  • Hong, Young Jin (The Committee on Infectious Diseases, The Korean Pediatric Society)
  • 김경효 (대한소아과학회 감염위원회) ;
  • 김종현 (대한소아과학회 감염위원회) ;
  • 박수은 (대한소아과학회 감염위원회) ;
  • 신선희 (대한소아과학회 감염위원회) ;
  • 오성희 (대한소아과학회 감염위원회) ;
  • 이환종 (대한소아과학회 감염위원회) ;
  • 조대선 (대한소아과학회 감염위원회) ;
  • 최은화 (대한소아과학회 감염위원회) ;
  • 허재균 (대한소아과학회 감염위원회) ;
  • 홍영진 (대한소아과학회 감염위원회)
  • Published : 2007.08.15
Download PDF
⟨ Previous Next ⟩

Abstract

Keywords

References

  1. Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson H, Unger ER. Centers for Disease Control and Prevention (CDC); Advisory Committee on Immunization Practices (ACIP). Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2007;56 (RR-2):1-24
  2. American Academy of Pediatrics Committee on Infectious Diseases. Recommended immunization schedules for children and adolescents-United States, 2007. Pediatrics 2007; 119:207-8 https://doi.org/10.1542/peds.2006-3309
  3. Saslow D, Castle PE, Cox JT, Davey DD, Einstein MH, Ferris DG, et al. American Cancer Society Guideline for Human Papillomavirus (HPV) Vaccine Use to Prevent Cervical Cancer and Its Precursors. CA Cancer J Clin 2007; 57:7-28 https://doi.org/10.3322/canjclin.57.1.7
  4. Preparing for the introduction of HPV vaccines, Policy and programme guidance for countries. http://www.fda.gov/cber/products/hpvmer060806.htm
  5. Pollack AE, Balkin M, Edouard L, Cutts F, Broutet N. WHO/UNFPA Working Group on Sexual and Reproductive Health and HPV Vaccines. Ensuring access to HPV vaccines through integrated services: a reproductive health perspective. Bull World Health Organ 2007;85:57-63 https://doi.org/10.2471/BLT.06.034397
  6. Soldan K, Dillner J. Comparable strategies needed to evaluate human papillomavirus vaccine efficiency across Europe. Euro Surveill 2006;11:E061123.3
  7. Kudjawu Y, Lévy-Bruhl D, Pastore Celentano L, O' Flanagan D, Salmaso S, Lopalco P, et al. The current status of HPV and rotavirus vaccines in national immunisation schedules in the EU-preliminary results of a VENICE survey. Euro Surveill 2007;12:E070426.1
  8. Schiller JT, Lowy DR. Human papillomavirus vaccines for cervical cancer prevention. In : Plotkin SA, Orenstein WA, Offit PA, editors. Vaccines. 4th ed. WB Saunders Co, 2004: 1259-65
  9. Bonnez W, Reichman RC. Papillomaviruses. In : Mandell GL, Bennet JE, Dolin R, editors. Principles and practice of Infectious Disease. 6th ed. Elsevior Inc., 2005:1841-55
  10. Lowy DR, Schiller JT. Prophylactic human papillomavirus vaccines. J Clin Invest 2006;116:1167-73 https://doi.org/10.1172/JCI28607
  11. Kahn JA. Vaccination as a prevention strategy for human papillomavirus-related diseases. J Adolesc Health 2005;37(6 Suppl):S10-S16 https://doi.org/10.1016/j.jadohealth.2005.08.018
  12. Stanley M. Immune responses to human papillomavirus. Vaccine 2006;24 Suppl 1:S16-22 https://doi.org/10.1016/j.vaccine.2005.09.002
  13. Noad R, Roy P. Virus-like particles as immunogens. Trends Microbiol 2003;11:438-44 https://doi.org/10.1016/S0966-842X(03)00208-7
  14. Shin HR, Franceschi S, Vaccarella S, Roh JW, Ju YH, Oh JK, et al. Prevalence and determinants of genital infection with papillomavirus, in female and male university students in Busan, South Korea. J Infect Dis 2004;190:468-76 https://doi.org/10.1086/421279
  15. Shin HR, Lee DH, Herrero R, Smith JS, Vaccarella S, Hong SH, et al. Prevalence of human papillomavirus infection in women in Busan, South Korea. Int J Cancer 2003; 103:413-21 https://doi.org/10.1002/ijc.10825
  16. Hwang HS, Park M, Lee SY, Kwon KH, Pang MG. Distribution and prevalence of human papillomavirus genotypes in routine pap smear of 2,470 Korean women determined by DNA chip. Cancer Epidemiol Biomarkers Prev 2004;13:2153-6
  17. Choi BS, Kim O, Park MS, Kim KS, Jeong JK, Lee JS. Genital human papillomavirus genotyping by HPV oligonucleotide microarray in Korean commercial sex workers. J Med Virol 2003;71:440-5 https://doi.org/10.1002/jmv.10498
  18. An HJ, Cho NH, Lee SY, Kim IH, Lee C, Kim SJ, Mun MS, Kim SH, Jeong JK. Correlation of cervical carcinoma and precancerous lesions with human papillomavirus (HPV) genotypes detected with the HPV DNA chip microarray method. Cancer 2003;97:1672-80 https://doi.org/10.1002/cncr.11235
  19. Reisinger KS, Block SL, Lazcano-Ponce E, Samakoses R, Esser MT, Erick J, et al. Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial. Pediatr Infect Dis J 2007;26:201-9 https://doi.org/10.1097/01.inf.0000253970.29190.5a
  20. Block SL, Nolan T, Sattler C, Barr E, Giacoletti KE, Marchant CD, et al. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics 2006;118:2135-45 https://doi.org/10.1542/peds.2006-0461
  21. 신해림, 서경, 송기준, 박은철, 최귀선, 이후연 등. 인유두종바이러스(HPV) 감염과 관련된 질병부담조사. 2007년 질병관리본부 용역연구과제 중간보고서